Abcam, plc Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting
Abcam plc (Nasdaq: ABCM) announced the publication of its 2022 Annual Report and Accounts, following the release of its final results for the year ended December 31, 2022, on March 20, 2023. The documents are accessible through Abcam's website, and hard copies will be sent to shareholders who opted for paper communications. The Annual General Meeting notice is included in this publication. Abcam, a leader in life science research tools, aims to support researchers globally with highly validated antibodies and assays, enhancing confidence in their results. Founded in 1998 and headquartered in Cambridge, UK, Abcam serves approximately 750,000 researchers in over 130 countries.
- Publication of the 2022 Annual Report and Accounts enhances transparency for investors.
- Abcam's strong customer base of approximately 750,000 life science researchers indicates robust demand for its products.
- None.
CAMBRIDGE, England and WALTHAM, Mass., March 30, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 20 March 2023 of its final results for the year ended 31 December 2022 on Form 20-F with the Securities and Exchange Commission, the Abcam plc Annual Report and Accounts 2022 (the "Annual Report") have been published today and are available on the Abcam plc website at corporate.abcam.com
The Annual Report will also be posted today, together with the Notice of Annual General Meeting, to those shareholders that have elected to receive paper communications. Shareholders that have not elected to receive paper communications will be notified of the availability of these documents on Abcam plc website at corporate.abcam.com. The Form 20-F can also be accessed on the Abcam plc website at corporate.abcam.com. Shareholders that have not elected to receive paper communications may still receive a hard copy of these documents upon request.
For further information, please contact:
Abcam
Tommy Thomas, CPA, Vice President, Investor Relations, +1 617 577 4205, tommy.thomas@abcam.com
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information, please visit corporate.abcam.com.
View original content:https://www.prnewswire.com/news-releases/abcam-plc-publication-of-2022-annual-report-and-accounts-and-notice-of-annual-general-meeting-301785708.html
SOURCE Abcam plc
FAQ
When was Abcam's Annual Report for 2022 published?
Where can I find the 2022 Annual Report for Abcam?
What significant events occurred for Abcam on March 30, 2023?
How many researchers does Abcam serve?
What is the stock symbol for Abcam?
